If a variant has more than two submissions, it may have multiple conflicts and therefore be counted in more than one conflict column. If this is the case, the "Variants with any kind of conflict" cell will be less than the sum of the conflicted variants cells to its left.
| Variants with only 1 submission per condition | Variants with at least 2 submissions on the same condition and no conflicts |
Variants with a synonymous conflict (e.g. benign vs non-pathogenic) |
Variants with a confidence conflict (e.g. benign vs likely benign) |
Variants with a benign or likely benign vs uncertain conflict |
Variants with a category conflict (e.g. benign vs affects) |
Variants with a clinically significant conflict (e.g. benign vs pathogenic) |
Variants with any conflict |
|---|---|---|---|---|---|---|---|
| 29 | 4 | 0 | 17 | 0 | 1 | 2 | 19 |
Significance breakdown #
In the table below, cells that correspond to a term paired with itself represent synonymous conflicts, i.e. variants that have been annotated with different terms that map to the same standard term. To compare the terms that were actually submitted, check the box in the filters section at the top of this page.
| All conditions | ||||
|---|---|---|---|---|
| Papillary renal cell carcinoma, sporadic | pathogenic | uncertain significance | drug response | |
| likely pathogenic | 17 | 2 | 1 | |
Condition to condition summary #
Total conditions: 21
| Condition | Variants with only 1 submission per condition | Variants with at least 2 submissions on the same condition and no conflicts |
Variants with a synonymous conflict (e.g. benign vs non-pathogenic) |
Variants with a confidence conflict (e.g. benign vs likely benign) |
Variants with a benign or likely benign vs uncertain conflict |
Variants with a category conflict (e.g. benign vs affects) |
Variants with a clinically significant conflict (e.g. benign vs pathogenic) |
Variants with any conflict |
|---|---|---|---|---|---|---|---|---|
| not provided | 0 | 4 | 0 | 14 | 0 | 0 | 2 | 15 |
| Abnormal cardiovascular system morphology | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 |
| PIK3CA related overgrowth syndrome | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 |
| See cases | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 |
| Cerebrofacial Vascular Metameric Syndrome (CVMS) | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| HEMIFACIAL MYOHYPERPLASIA, SOMATIC | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| Nevus sebaceous | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| Astrocytoma, low-grade, somatic | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| BRAF-related condition | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| CEREBRAL CAVERNOUS MALFORMATIONS 4, SOMATIC | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Cardiovascular phenotype | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Cystic epithelial invagination containing papillae lined by columnar epithelium | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Eccrine Angiomatous Hamartoma | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Epidermal nevus with urothelial cancer, somatic | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| FGFR3-related condition | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| HRAS-related condition | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Histone Methylation Therapy response | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| OVARIAN CANCER, EPITHELIAL, SOMATIC | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| PIK3CA-related condition | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Segmental undergrowth associated with lymphatic malformation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| TP53-related condition | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
All variants with conflicting interpretations #
Total variants: 19